ALLERGENS BASED ON RECOMBINANT PROTEINS
Аbout 30-40 % of the world’s population suffer from various allergological diseases, which are based on a specific reaction of the body (hypersensitivity) to allergens. For the diagnosis and treatment of allergic diseases, allergen preparations are used. Initially, allergen preparations were obtained only from natural sources-plant pollen, animal hair (epithelium), domestic dust, food, etc. Now more than a few hundred protein allergen sequences are known, which made it possible to create a large number of recombinant allergen proteins. Recombinant allergens are used as novel products in allergodiagnosis and immunotherapy of allergic diseases. The use of recombinant allergens in diagnostic kits based on immunoassay methods such as ELISA or REAST, as well as in molecular diagnostics, is widely used. The first recombinant products has appeared over 15 years ago. Clinical studies showed that therapeutic efficacy of these drugs is not inferior to commercial, but studies assessing the efficacy and safety of Allergology based on recombinant proteins is still not finished. Recombinant allergens are recommended as standards for the determination of allergenic activity and for the standardization and validation of ELISA-based methods. The results of research conducted using recombinant allergens have expanded our knowledge of the structure and properties of allergens, allowed to create a classification based on their structural homology and cross reactivity.
About the authorsNevskaya Larisa Valer’evna
Pawankar R., Canonica G.W., Holgate S.T., Lockey R.F. Allergic Diseases as a Global. Public Health Issue. White Book on Allergy (World Allergy Organization (WAO)). 2011; 11-20.
Allergen nomenclature. Bulletin of WHO. 1994; 72 (2): 797-806.
Thomas W.R., Stewart G.A., Simpson R.I., et al. Cloning and expression of DNA coding for the major house dust mite allergen Der p I in Escherichia coli. Int. Arch. Allergy Appl. Immunol. 1988; 85: 127-9.
Curin M., Garib V., Valenta R. Single recombinant and purified major allergens and peptides how they are made and how they change allergy diagnosis and treatment. Ann. Allergy Asthma Immunol. 2017;119: 201-9.
Akkerdaas J.H., Wensing M., Knulst A.C., Aalberse R.C., Hefle S.L., van Ree R. In vitro and in vivo characterization of hazelnut skin prick test extracts. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe. Frankf A.M. 2003; 87-95.
Kespohl S., Maryska S., Zahradnik E., Sander I., Brüning T., Raulf-Heimsoth M. Biochemical and immunological analysis of mould skinprick test solution: current status of standardization. Clin. Exp. Allergy. 2013; 43: 1286-96.
Lundberg M., Chen Z., Rihs H.P., Wrangsjö K. Recombinant spiked allergen extract. Allergy. 2001; 56: 794-5.
Andersson K., Ballmer-Weber B.K., Cistero-Bahima A., et al. Enhancement of hazelnut extract for IgE testing by recombinant allergen spiking. Allergy. 2007; 62: 897-904.
Pavlov A.V., Salieva N., Mukhortykh O.Yu., Stefanov V.E. Obtaining and evaluating analog to the recombinant major allergen of birch pollen Bet v 1. Rossiyskiy allergologicheskiy zhurnal. 2012; 3: 7-13. (in russian)
Salieva N.A. Vertigo E.A. production and properties of allergiamentes protein eggs. In St. Clinical immunology and Allergology - interdisciplinary problems may 14-17. [Klinicheskaya immunologiya i allergologiya - mezhdistsiplinarnye problemy, may 14-17]. 2014; Kazan: 237-8. (in Russian)
Villalta D., Tonutti E., Bizzaro N., et al. Recommendations for the use of molecular diagnostics in the diagnosis of allergic diseases. Eur. Ann. Allergy Clin. Immunol. 2018; 50 (2): 52-9.
Lupinek C., Wollmann E., Baar A., et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. Methods. 2014; 66:106-19.
Mokronosova M. A., Korovkina E. S. Component diagnostics - a new era in clinical Allergology. Therapeutic archive. 2013; 10: 4-9. (in Russian)
Smoldovskaya O.V., Voloshin S.A. Feyzkhanova G.U., et al. Application of multiplex fluorescent immunoassay on biochips for screening in allergodiagnostics: comparison of the results with test systems MAST-CLA and ALLERG-O-LIQ. Immunologiya. 2015; 6: 358-62.
Valenta B., Linhart I., Swoboda1 V. Niederberger Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy. 2011; 66: 775-83.
Ferreira F., Wolf M., Wallner M. Molecular approach to allergy diagnosis and therapy. Yonsei Med. J. 2014; 55: 839-52.
Pauli G., Purohit A., Oster J.P., de Blay F., Vrtala S., Niederberger V. et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin. Exp. Allergy. 2000; 30: 1076-84.
Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P. et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA. 2004; 101(suppl 2): 14677-82.
Pauli G., Larsen T.H., Rak S., et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2008; 122: 951-60.
Klimek L., Bachert C., Lukat K.F., Pfaar O., Meyer H., Narkus A. Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin. Transl. Allergy. 2015; 5: 28.
Nony E., Bouley J., Le Mignon M., et al. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients. Allergy. 2015; 70: 795-804.
Rak S. Clinical results with a hypoallergenic recombinant birch pollen allergen derivative. 2009. Presented at 27th Congr., EAACI. 2009; Warsaw: 6-10.
Larenas-Linnemann D. Oralair Birch, A recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Curr. Opin Investig Drugs. 2010;11: 586-96.
Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 2005; 116: 608-13.
Zieglmayer P., Focke-Tejkl M., Schmutz R., Lemell P., Zieglmayer R., Weber M. et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine. 2016; 11: 43-57.
Senti G., Crameri R., Kuster D., et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J. Allergy Clin. Immunol. 2012; 129: 1290-6.
Wood R.A., Sicherer S.H., Burks A.W, et al. A phase 1 study of heat/phenol-killed, E. coli -encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 2013; 68: 803-8.
Jongejan L., van Ree R., Poulsen L.K. Hypoallergenic molecules for subcutaneous immunotherapy. Expert Rev. Clin. Immunol. 2016; 12: 5-7.
Jutel M., Kosowska A., Smolinska S. Allergenimmunotherapy: past, present, and future. Allergy Asthma Immunol. Res. 2016; 8: 191-7.
Tscheppe A., Breiteneder H. Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy Int. Arch. Allergy Immunol. 2017; 172: 187-202.
Cramery R. Allergy vaccines: dream and reality. Expert Rev. Vaccines. 2007; 6(6): 991-9.
Committee for medicinal products for human use, guideline on allergen products: production and quality issues. European Medicines Agency; London: 2008. Available from: http://www.emea.europa.eu.
Soldatov A.A., Medunitsyn N.V., Avdeeva Z.I., Bondarev V.P., Mironov A.N. Medicinal allergen preparations, problems and ways to improve quality, safety and efficiency. Vedomosti nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya. 2013; (4): 31-7. (in Russian)
Nevskaya L.V., Lavrenchik E.I., Zhdanova M.Yu., Fadeykina O.V., Kapitanova VK. International practice of standardization of allergen products. Biopreparaty. Profilaktika, diagnostika, lechenie. 2017; 17 (4): 222-9. (in Russian)
Chapman M.D., Fereira F., Villalba M., et al., The European Union CREATE Project: A model for international standardization of allergy diagnostics and vaccines. J. Allergy Clin. Immunol. 2008; 122 (5): 882-9. Vieths S., Barber D., Chapman M. et al. Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. Reference standards and validation of ELISA methods for their measurement. Pharmeuropa Bio&SN 2012; 118-34.
Mas S., Boissy P., Monsalve R.I., Cuesta-Herranz J. et al. A recombinant Sal k 1 isoform as an alternative to the polymorphic Allergen from Salsola kali pollen for allergy diagnosis. Int. Arch. Allergy Immunol. 2015; 167: 83-93.
- Refbacks are not listed
Контент доступен под лицензией Creative Commons Attribution 3.0 License.